Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019045075) IL-33 ANTAGONIST-CONTAINING THERAPEUTIC AGENT FOR ENDOMETRIOSIS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/045075 International Application No.: PCT/JP2018/032494
Publication Date: 07.03.2019 International Filing Date: 31.08.2018
IPC:
A61K 45/00 (2006.01) ,A61K 38/17 (2006.01) ,A61K 39/395 (2006.01) ,A61K 47/68 (2017.01) ,A61P 15/00 (2006.01) ,C07K 16/24 (2006.01) ,C07K 19/00 (2006.01) ,C12N 15/113 (2010.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
[IPC code unknown for A61K 47/68]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15
Drugs for genital or sexual disorders; Contraceptives
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
24
against cytokines, lymphokines or interferons
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
19
Hybrid peptides
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
113
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Applicants:
田辺三菱製薬株式会社 MITSUBISHI TANABE PHARMA CORPORATION [JP/JP]; 大阪府大阪市中央区道修町三丁目2番10号 3-2-10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 5418505, JP
学校法人兵庫医科大学 HYOGO COLLEGE OF MEDICINE [JP/JP]; 兵庫県西宮市武庫川町1番1号 1-1, Mukogawa-cho, Nishinomiya-shi, Hyogo 6638501, JP
Inventors:
善本 知広 YOSHIMOTO, Tomohiro; JP
パルンボ エム ジョセフ PALUMBO, M. Joseph; US
ストーン アイ ヴィオレッタ STONE, I. Violetta; US
加藤 徹 KATO, Toru; JP
安田 好文 YASUDA, Koubun; JP
Agent:
青木 篤 AOKI, Atsushi; JP
三橋 真二 MITSUHASHI, Shinji; JP
渡辺 陽一 WATANABE, Yoichi; JP
中島 勝 NAKAJIMA, Masaru; JP
武居 良太郎 TAKEI, Ryotaro; JP
津田 英直 TSUDA, Hidenao; JP
Priority Data:
62/552,59431.08.2017US
Title (EN) IL-33 ANTAGONIST-CONTAINING THERAPEUTIC AGENT FOR ENDOMETRIOSIS
(FR) AGENT THÉRAPEUTIQUE CONTENANT UN ANTAGONISTE DE L'IL-33 POUR TRAITER L'ENDOMÉTRIOSE
(JA) IL-33アンタゴニストを含む子宮内膜症治療剤
Abstract:
(EN) To provide a therapeutic agent for endometriosis and adenomyosis. IL-33 was identified as an exacerbating factor in endometriosis and adenomyosis, and an IL-33 antagonist, which is capable of inhibiting the function of IL-33, was found to be useful for treating, preventing or alleviating endometriosis and uterine adenomyosis.
(FR) L'invention concerne un agent thérapeutique pour traiter l'endométriose et l'adénomyose. L'IL-33 a été identifiée comme étant un facteur d'exacerbation dans l'endométriose et l'adénomyose, et un antagoniste de l'IL-33, lequel est capable d'inhiber la fonction de IL-33, s'est avéré utile pour traiter, prévenir ou soulager l'endométriose et l'adénomyose utérine.
(JA) 子宮内膜症又は子宮腺筋症の治療剤を提供すること。 IL-33が子宮内膜症又は子宮腺筋症の悪化因子であることを特定し、IL-33の作用を阻害することができるIL-33アンタゴニストが、子宮内膜症又は子宮腺筋症の治療、予防、又は軽減に有用であることを見出した。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)